Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab A/S announced the disclosure of share transactions by managerial employees and their closely associated persons in accordance with market abuse regulations. The company also announced a capital increase of 164,828 shares resulting from employee warrant exercises.

11/10/2026, 5:57 PM • GlobeNewswire

Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

Genmab announced that 22 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody, will be presented at the 2026 ASH Annual Meeting in December. Highlights include first presentation of Phase 3 EPCORE DLBCL-4 study results showing epcoritamab plus lenalidomide in relapsed/refractory DLBCL, along with updated data from multiple trials across B-cell malignancies demonstrating the drug's versatility as monotherapy and in combinations.

11/04/2026, 9:00 AM • GlobeNewswire

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Genmab announced updated Phase 2 trial results for petosemtamab, a bispecific antibody targeting EGFR and LGR5, showing encouraging objective response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer patients when combined with standard chemotherapy. The data demonstrates durable responses and supports the ongoing global Phase 3 development program.

10/25/2026, 7:00 AM • GlobeNewswire

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab and Incyte announced a Phase 1/2 clinical trial collaboration to evaluate petosemtamab combined with INCB161734 and standard-of-care chemotherapy as a first-line treatment for patients with KRAS G12D-mutated metastatic colorectal cancer. Genmab will conduct the study while Incyte will co-fund and provide clinical supply of INCB161734.

10/24/2026, 7:00 AM • GlobeNewswire

Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge

The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.

10/05/2026, 5:13 PM • The Motley Fool

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab and AbbVie announced positive Phase 3 trial results for epcoritamab combined with R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The combination demonstrated a statistically significant 51% reduction in disease progression or death risk compared to R-CHOP alone, with a favorable safety profile. This marks the first Phase 3 study of a bispecific antibody combination to show significant improvement in progression-free survival in frontline DLBCL treatment.

10/05/2026, 2:49 PM • GlobeNewswire

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab announced Phase 2 results for Rina-S (rinatabart sesutecan) in platinum-resistant ovarian cancer, demonstrating a 45.9% objective response rate with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. The drug showed antitumor activity regardless of folate receptor alpha expression levels, with manageable tolerability. The company is advancing four Phase 3 trials across multiple gynecologic cancers.

10/03/2026, 3:40 PM • GlobeNewswire

Major Shareholder Announcement

Darwin Global Management Limited has disclosed a significant shareholding in Genmab A/S, controlling 3,188,361 shares and ADRs representing 5.11% of voting rights as of September 28, 2026. The announcement was made under Danish Capital Markets Act requirements.

10/02/2026, 1:50 PM • GlobeNewswire

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab A/S announced the grant of 13,794 restricted stock units and 13,331 warrants to employees. The RSUs have a fair value of DKK 2,268 per unit and will vest after three years, while warrants have an exercise price of DKK 2,268 with a Black-Scholes fair value of DKK 781.96, vesting in three years and expiring after seven years.

09/24/2026, 2:32 PM • GlobeNewswire

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S announced a capital increase of 28,011 shares resulting from employee warrant exercises, raising approximately DKK 44.3 million. The new shares represent 0.04% of the company's share capital and will be listed on Nasdaq Copenhagen. The total nominal share capital after the increase is DKK 62,405,855.

09/08/2026, 2:44 PM • GlobeNewswire

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

09/03/2026, 1:00 PM • GlobeNewswire

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie announced that the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab (a T-cell engaging bispecific antibody) failed to meet its primary endpoint of overall survival in the United States when compared to standard chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Despite the trial failure, epcoritamab remains approved under accelerated approval and the companies continue to evaluate the therapy in other clinical programs.

07/23/2026, 4:00 PM • GlobeNewswire

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

07/13/2026, 1:00 PM • GlobeNewswire